`IBC International Conference on
`
`December 16-18, 1991 • Omni San Diego Hotel •San Diego, CA
`
`Organized by: •
`
`International Busines..4' Communications
`
`me USA Conference Inc. • 8 Plea ant Street, Bldg. D • South Natick, Mass. 01760
`(508) 650--4700
`
`1 of 6
`
`Celltrion, Inc., Exhibit 1120
`
`
`
`WELCOME
`
`IBC USA Conferences welcomes you co Antibody Engineering.
`
`No meeting is truly successful if it simply serves the purpose of transferring information. We hope
`in[eractions between lhe speakers and Lhe audience will be1p you gain insights rhac you can use today.
`
`We strongly encourage your participation throughout the conference and have allowed time for you
`~se questions co the speakers. Ample rime for informal interactions has also been allocaced
`oughouc the day. These encounters will complement both the speaker pn:sentations and the written
`·erial.
`
`Our staff members are available throughout the conference to provide assiscance. Please do not
`~tate [Q call on us. We thank you for joining us!
`
`~J!Jl
`
`Phillips Kuhl
`Conference Director
`
`6# ~~-/ 44-/
`Gail Scho
`Conference Manager
`
`Susan Hamano
`Christine Andrews
`Conference Coordinator
`Conference Coordinacor
`!BC USA Conferences
`
`~ Delegates are required to wear their bat$ges at all times. Those without their badges will not be admitted.
`
`2 of 6
`
`Celltrion, Inc., Exhibit 1120
`
`
`
`ANTIBODY ENGINEERING
`
`Schedule of Events
`
`Welcome & Introduction • Speaker Contacts • Speaker Presentations
`
`Sunday, December 15, 1991
`
`p.m.-10:30 p.m. Early Registration
`
`Monday, December 16, 1991
`
`~. a.m.-8:30 a.m.
`
`Rtgmrauon, Poster St1-up & Cof!u
`
`ENGINEERING TO AVOID HAMA
`CHAIRMAN'S OPENING REMARK
`Dr. Sherif L Morrl\on, Pro/tsS()r of M1crobwlor1 and Molecular Gene1irs, Member of the Moucwlar Bialogy /1U1il11'U, UCLA
`
`8:30
`
`8:35 HUMANIZED Al\TIBODIES FOR THERAPY
`Dr. Cary Qurrn, Vice Preside.111, Resca~h. Proteut Design Lab.f, Inc
`
`9:05
`
`FRAMEWORK CHOICE & RESIDUE SUBSTlTUTION FOR HUMANIZE D
`VENEERED ANTIBODIE
`Dr. G~orae E. Mark ID, D;,1ec1or, Ct'llular &. Mole4ular Bwlofl), Mud SJi/Jrp &. DoivnL RCRarch LaborOJOriu
`
`9:35 USE OP A VACCINIAfli SYSTEM TO RAPIDLY ANALYZE HUMA1'1ZED & OTHER
`ENGINEERED SJNGLE-CHArN FV'S
`Dr. S)·d Johnson, R1.1~h Sc~NISI. Mcdlmnu<nt!, I~
`
`10:05
`
`Rtfrtshment Brtak & Posttrs
`
`10:45
`
`11:15
`
`FUNCTIONAL ANALYSIS OF HlJMA1'1ZED OKTJ & OKT4A
`Dr. Ro~rt A. Zh In, Pn.ocipal Sc~1111n, 810/ech. R W Johl'ISOl'I Phannauiuical R~ic ln.s1uuu
`
`BIOACTIVE PEPTIDE DESIGN BASED ON ANTIBODY HYPERVARIABLE REGION STRUCTURE
`Dr. Will lam V. Wllllams, Di!partmDlJ of Me.dJL~ lru\lus1ry of Pmn.ry/wJnill School of MrdiciN
`
`11:45 ORAL PRESENTATION OF SELECTED POSTERS
`
`12:00
`
`PANEL DISCl:SSION
`
`12:30
`
`Lu.ncheon
`
`EXPRESSION & ENGINEERING
`
`I :~.5 CHA IR~1Al\' REMARK
`Or. James D. M11rks, Rularch Sc~nJtsr. Medical Rt~~arch Cowteil lUK 1
`
`1:50 ANTIBODY E~G~EERING RY E1"ZYMATIC IJ'WERSE PCR
`Dr. Wlllrm P. C. 1emmer. Seruor Rt~larch Srnwi.11. H)brru:cic, /nc
`
`2:20 MAK.11\G Hl"1Al'i A~TIBODIES U ING PHAGE ' £LECTIO.
`Dr. James D. \1urks
`
`3 of 6
`
`Celltrion, Inc., Exhibit 1120
`
`
`
`2:50
`
`IN VITRO AFFINITY MATURATION BY SITE DIRECTED MUTAGENESIS
`Dr. WUJlam D. Hme, CN.ef Sc10tJiflc Officer. IXSYS. Inc
`
`3:20 Rtfru hmen1 Break & Postt rs
`
`4:00 ANTIBODY ENGINEERING FOR MICROBIAL EXPRESSION & THERAPEUTIC USE
`Dr. A mold H. Hon.tu, Dvt!ctor of Molttwlar Mu:robiology, XOMA Corpora11.0n
`
`4 :30
`
`R ECENT ADVANCES WITH CATALYTIC A.NTIBODIES
`Dr. Mark A.. Gallop, S1ajf Scienlist, B ioorganic CJmmstry, A]hm.tlx Rtsearch /ns1ui.u
`
`5:00 ORAL PRESENTATION OF SELECTED POSTERS
`
`5:15
`
`PANEL DISCUSSION
`
`5:45 Clo.st! of Day Ont
`
`Tuesday, December 17, 1991
`
`7:30 Coffu &: Pos11m.
`
`Bl-SPECIFIC & Bl-FUNCTIONAL
`
`8:00 CHAIRMAN' S RF.MARKS
`Dr. SMrle L. Murraon, Professm of M1uob1olo1fY ll1lil Molt!t:ulcv Gmt1ics. Mtmbtr of'"' Mokcular Biology /11S1itwie. UCLA
`
`8:05 OVERCOMING ANTIDODY BLOCKAGE USING Bl-SPECIFIC ANTIBODIES
`Dr. Satban 8 . Dlnces, \'ice Prtsidefll Mtd.aru. Inc
`
`8'.35
`
`9:05
`
`RF.SF.A RCH & CLJNICAL EXPERIEJ\CE WITH 81-SPEc m c ANTIBODIES
`Dr. Joesph G. Major, Sef'l.IOr Resrwch Sc11n11s:, H}bmcch, /ncorporaud
`
`TARGETING C YTOTOXJCIT\' WITH A Bl-SPECIFIC ANTIBODY DIRECTED TO
`C-ERB-2 & HUMAN FC"y RECEPTOR Ill
`Dr. Dnld 8 . Ring, SMWr Sc1cnJut. Dvecior. Dt:JX1rlme1t1 of lmnumoloi). Ct!1w.t CorportJJ1on
`
`9 35 Refrtshmem BreaJ. & Pos1ers
`
`10:15
`
`PRODUCTION OF A SINGLE-CHAIN Bl·SPECIF1C ANTIBODY
`Dr. Andttw J. T. Gfl>rgr , £xpu~n1al lmnuuiolou Branrh, /\aJwnal Can£U /n.rriwu , Na1iona/ lnstilwu.s of H t:ahh
`
`10:45 GENETIC ENGINEERING Of ASTIBODIES FOR NOVEL FUNCTIONS
`Dr. herle L. ~ o rris.on
`
`11 : 15 ORAL PRESENTATION Of SELECTED POSTERS
`
`l 1:30
`
`PANEL DL'iCL'SSION
`
`12:00
`
`lunch Br~alr.
`
`HUMAN MONOCLONALS
`
`1:15
`
`C HAIRMA1'' S RF.MARKS
`Dr. \1urk C. Ght.~} . Edi1or 111 -Clut:/, Humlll1Afllibodi~s aNJ llybridomaJ and Prt:sidm. Sc1-CloM, Jnc.
`
`1:20 HUMA"li MONOCLONAL IMAGJ'iEERJl\G
`Dr. !\tan. C. Gia&)
`
`1:50 HUMA1' A'ITJBODIES B\' RF:PERTOIRE L'LO!' l:"JG
`Dr. Carl05 F. B .. rb~, .>\.uu1an1 Prvfe.rn., Scripr" Re\tJn h Jnswu.u
`
`4 of 6
`
`Celltrion, Inc., Exhibit 1120
`
`
`
`2:20
`
`PRODUCTION &c APPLICATION OF HUMAN MONOCLONAL ANTIBODIES
`Dr. S. M. Jwasa, Ru~ardt MDNJ10. Bwlog)' Res~n l.AboratonCJ, TaiwJJJ ClwluC41 /ndlUlria, LJd.
`
`2:50 Refreshment Break & Postus
`
`3:30
`
`IN VITRO IMMUNIZATION METHODS FOR PRODUCTION OF HUMAN IGG
`MONOCLONAL ANTIBODIES
`Dr. Paula Boerner, Dirttl"' of Celi Baolog:-. IXSYS. Inc
`
`4:00 DEVELOPMENT OF A HUMAN lrt1MllNOGLOBULIN TRANSGENIC MOUSE
`Dr. Slls Loabrr&, SotJDT Scu:fllUt. Genl'lw.rm buul'IQliQNJJ
`
`4:30 ORAL PRESENTATION OF SELECTED POSTERS
`
`4:45
`
`PANEL DISCUSSION
`
`5: 15
`
`POSTERS
`
`6:00 Cocklail Rtception
`
`7:30 Close of Day T"'"'
`
`'tVednesday, Decernber1B. 1991
`
`7:30 Coffu & Posrtrs
`
`CLINICAL EXPERIENCE
`
`8:00 CHAIRMAN'S REMARKS
`Dr. Albfrt F. LoBugflo, D1ncror Compr~MllJm Cancer Cefllu, Professor of MemciM, Univvsll) of Alabama a18inn111gltam
`
`8:05
`
`8:35
`
`PHARMACOKINETICS & 11.fMUNE RESPO~SE OF MURINE & CHIMERIC ANTIBODIES
`Dr. AJbtrt F. LoBugJlo
`
`CLINICAL EXPERIENCE WITH THE L6 A"ffl·CARCINO\!A ANTIBODY
`Dr. Dalt' E. Yt!lton, SciLNISI, Brmol-M)u.r Sq1,.bb Pharm.xewicat Research l1U11lllll
`
`9:05 CLINICAL RESULTS WITH CHIMERIC & HUMAN MONOCLONAL ANTIBODIES
`Dr. Jamti N. Wood~, Suu01T \-'iu PresuitnJ, C miocor. ll'IC
`
`9:35 Refreshment Bnak and Poscers
`
`10:15
`
`10:45
`
`PATIE1'T RESPONSE TO CHIMERIC 872.3
`l>r. Ttrt) S. Bakrr, Pr111C1pat Sc~111is1. Crlltuh, ud
`
`IJliTERNAL IMAGE ANTIGEJ'liS AS THERAPEUTIC MODA.LITTF.S FOR CANCER &
`INFECTIOUS DISEASES
`Dr. Samurl D. Waksal, P~s1dU1J and CEO. JmCJ.oM 51.rtmu Inc
`
`11:J5 ORAL PRESENTATION OF ELECTED POSTER
`
`11 :30
`
`PA!liEL DI Cl: 'SIOJ'li
`
`12:00
`
`Clos~ of Conftr~nu
`
`5 of 6
`
`Celltrion, Inc., Exhibit 1120
`
`
`
`CHOOSING THE BEST FRAMEWORK TO USE IN THE 'HUMANIZATION'
`OF AN ANTIBODY BY CCR-GRAFTING : SUGGESTIONS FROM 3-0
`STRUCTURAL DATA
`
`Eduardo A. Padlan
`Laboratory of Molecular Biology, National Institute of Diabetes and
`Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
`Maryland 20892, U.S.A.
`
`SUMMARY
`
`In order to ensure the preservation of antigen-binding properties.
`when an antibody is 'humanized' by CDR-grafting, all the framework
`residues, that could influence the structure of its combin ing site, must be
`retained. Examination of the structures of various Fabs reveals that those
`residues are different for different antibodies, emphas1Z1ng the need for a
`we ll-characterized, three-d1mens1onal structure to serve as a guide
`during 'humanization'. A hypothetical 'humanization' by CDR-grafting of
`the mudne antibody, J539, that attempts to preserve the ligand-binding
`prupe:1·ties of th e molecule:, aer.1onstrates that hurnan 1mmunoglobulrn
`sequences are available that. w1 h only a few mu ations, could serve as
`the best framework for the 'humanization' of this antibody.
`
`6 of 6
`
`Celltrion, Inc., Exhibit 1120
`
`